LIXTE Joins Russell Microcap Index
LIXTE Joins Russell Microcap Index
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
The New Bottleneck Isn’t Computing Power — It’s Just Power
LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
Lixte Biotechnology (NASDAQ:LIXT) Trading Up 0.5% – Here’s Why
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities
LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology
LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers
LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)
LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor
LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
LIXTE Biotechnology Holdings Provides Corporate Update
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement
Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules